Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom

Warren, Richard B; Halliday, A; Graham, Christopher N.; Gilloteau, I.; Miles, LaStella; McBride, Doreen

doi:10.1111/jdv.15094

Cited by 8 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Previous randomized controlled trials (RCTs) have demonstrated that biologic therapies are associated with significant improvement in work productivity/reduced work impairment and a reduction in associated costs in patients with moderate-to-severe psoriasis. [9][10][11] However, there are limited reports on the effect of brodalumab, a human anti-interleukin-17 receptor monoclonal antibody approved for the treatment of plaque psoriasis, [12][13][14] on work productivity.…”

Section: Introductionmentioning

confidence: 99%

Work productivity in real‐life employed patients with plaque psoriasis: Results from the ProLOGUE study

Saeki

Kanai

Murotani

et al. 2022

The Journal of Dermatology

View full text Add to dashboard Cite

Psoriasis poses a substantial economic burden by reducing the work productivity of affected patients. We aimed to evaluate the negative impact of plaque psoriasis on work productivity and effectiveness of brodalumab in improving work productivity impairment in real-life employed patients. This analysis was conducted in employed patients from ProLOGUE, an open-label, multicenter, prospective cohort study (Japan Registry of Clinical Trials identifier: jRCTs031180037). Outcomes included association of Work Productivity and Activity Impairment-Psoriasis (WPAI-PSO) domain scores with scores from various patient-reported outcome measures or Psoriasis Area and Severity Index (PASI) scores at baseline. Change from baseline in WPAI-PSO domain scores following brodalumab treatment was also evaluated. Of the 73 patients enrolled, 51, 48, and 40 patients were considered employed at baseline, Week 12, and Week 48 of brodalumab treatment, respectively. In the model adjusted by age and sex, the work productivity loss score correlated with the Dermatology Life Quality Index (DLQI), itch Numeric Rating Scale (NRS), Patient Health Questionnaire-8 (PHQ-8), and skin pain NRS scores (partial Spearman correlation coefficient [ρ] = 0.608, 0.510, 0.461, and 0.424, respectively); presenteeism score correlated with the DLQI, itch NRS, and skin pain NRS scores (ρ = 0.568, 0.500, and 0.403, respectively); and activity impairment score correlated with the DLQI and PHQ-8 scores (ρ = 0.530 and 0.414, respectively). None of the WPAI-PSO domain scores correlated with the PASI score. All WPAI-PSO domain scores (except absenteeism) significantly reduced from baseline to Weeks 12 (p < 0.0001) and 48 (p < 0.001) with brodalumab treatment. In conclusion, work productivity impairment in psoriasis was associated with various subjective symptoms that can be captured using patientreported outcome measures. Brodalumab treatment improved work productivity in real-life employed patients with plaque psoriasis.

show abstract

Section: Introductionmentioning

confidence: 99%

Work productivity in real‐life employed patients with plaque psoriasis: Results from the ProLOGUE study

Saeki

Kanai

Murotani

et al. 2022

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…This has important long-term economic implications given that higher PASI responses were shown to be associated with reduced total work productivity impairment in patients with moderate-to-severe psoriasis [ 34 ]. Indeed, secukinumab was found to significantly reduce work impairment and psoriasis-associated indirect costs compared with ustekinumab and etanercept [ 35 ]. Furthermore, secukinumab has a more favorable safety profile and fewer contraindications than adalimumab [ 36 , 37 ]; for example, secukinumab carries lower risk of serious infections, demyelinating diseases, and reactivation of latent tuberculosis or hepatitis B, making it a preferred choice in some patients.…”

Section: Discussionmentioning

confidence: 99%

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease

et al. 2022

View full text Add to dashboard Cite

Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per responder of secukinumab versus adalimumab in patients with psoriatic disease. Methods: The cost per responder was calculated by multiplying the cost of treatment by the number needed to treat for each therapy. The 52-week primary endpoint was the American College of Rheumatology response rate (ACR) 20; secondary endpoints were ACR 50, Psoriasis Area and Severity Index (PASI) 90, and minimal disease activity (MDA). Results: The cost per responder for ACR 20 was €19,846 versus €19,766 for secukinumab and adalimumab, respectively, whereas the costs per responder for ACR 50 and PASI 90 were €27,820 versus €27,384 and €22,102 versus €32,375 for secukinumab and adalimumab, respectively. The cost per MDA responder was €34,072 and €38,906 for secukinumab versus adalimumab. Conclusions: The costs per responder associated with the psoriatic arthritis end points were similar for adalimumab and secukinumab; conversely, the costs for psoriasis and composite end points were lower for secukinumab.

show abstract

“…In a secondary analysis, compared with etanercept, the annual work-related indirect cost savings associated with secukinumab were £1017. In both cases, the indirect costs were calculated as the product of work productivity loss and the hourly wage data [ 24 ]. In an Italian study [ 44 ], the reduction of working capacity before the initiation of biologic treatment for chronic plaque psoriasis was 18.0 days per year, which reduced to 4.9 days with biologics.…”

Section: Discussionmentioning

confidence: 99%

“…PASI score is widely adopted for informing clinical decisions in plaque psoriasis treatment and is one of the main scores used in the S3 Guideline for the treatment of psoriasis vulgaris [ 12 ]. PASI ≥ 75 state was chosen as it has shown to correlate with improved work productivity for patients [ 24 ]. The objective of the statistical model was, therefore, to quantify the number of PASI ≥ 75 patient-years in two scenarios: Scenario I where the patients receive secukinumab as first-line treatment, and an alternative scenario (Scenario II) where the same patient population receives FAEs in first line.…”

Section: Methodsmentioning

confidence: 99%

The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation

Seddik

Melzer

Tsotra

et al. 2021

PharmacoEconomics Open

View full text Add to dashboard Cite

Objectives Moderate to severe plaque psoriasis is a chronic inflammatory disease. In Germany, guidelines recommend fumaric acid esters (FAEs) as first-line systemic treatment. Despite treatment with FAEs, disease burden remains high in Germany. Secukinumab, a fully human monoclonal antibody, has demonstrated greater efficacy and safety than FAEs in the PRIME trial. The aim of the current study, hence, is to quantify the potential societal economic impact of secukinumab in systemic treatment-naïve patients with moderate to severe plaque psoriasis in Germany. Methods We employed a semi-Markov model to capture health gains at an individual level and a dynamic population model to extrapolate the findings in the population of interest. We quantified the health outcomes in two scenarios: (i) patients receiving secukinumab and (ii) patients receiving FAEs. Using estimates on change in work productivity and societal economic parameters, we translated the health outcomes into paid and unpaid economic gains. We used gross value added (GVA) to value these gains and calculated the macroeconomic indirect and induced value-chain effects. Results Our calculations show that patients treated with secukinumab spend on average 94% of their time in Psoriasis Area and Severity Index (PASI) ≥ 75 state compared with 80% for patients in the FAEs scenario. When assuming that FAEs are the sole comparator to secukinumab, this difference could lead to 4.3 million active hours gained until 2030. These gained hours translate to a total societal economic impact of €308 million till 2030 for the whole patient population in GVA terms. Conclusion This study demonstrated that using secukinumab instead of FAEs in moderate to severe plaque psoriasis could lead to substantial macroeconomic GVA gains.

show abstract

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom

Abstract: Secukinumab significantly reduced work impairment and associated indirect costs of psoriasis compared with ustekinumab and etanercept at Week 16 through 52 in the United Kingdom.

Cited by 8 publications

References 23 publications

Work productivity in real‐life employed patients with plaque psoriasis: Results from the ProLOGUE study

Work productivity in real‐life employed patients with plaque psoriasis: Results from the ProLOGUE study

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease

The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation

Contact Info

Product

Resources

About